CMH :: Clinical and Molecular Hepatology

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Mas

Evolving therapeutic landscape of advanced hepatocellular carcinoma

Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, René Bernards, Wenxin Qin, Cun Wang

Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 203. CrossRef

Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice

Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka

Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients

Walizeb Khan, Washaakh Ahmad, Anwar M. Hashem, Shadi Zakai, Shafiul Haque, Muhammad Faraz Arshad Malik, Steve Harakeh, Farhan Haq

Journal of Clinical Medicine.2022; 11(11): 3093. CrossRef

Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy

Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco

AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy

Yun Feng, Dan Zhang, Gaixia He, Yaping Liu, Yan Zhao, Xiaoyang Ren, Huanhuan Sun, Guifang Lu, Zhiyong Zhang, Li Ren, Yan Yin, Hongxia Li, Shuixiang He

Anti-Cancer Agents in Medicinal Chemistry.2022; 22(18): 3107. CrossRef

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen

Therapeutic Advances in Medical Oncology.2021; 13: 175883592110180. CrossRef

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma

World Journal of Gastroenterology.2020; 26(3): 279. CrossRef

Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma

Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon

International Journal of Molecular Sciences.2020; 21(2): 472. CrossRef

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satos

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin

The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma

Current Hepatology Reports.2019; 18(4): 371. CrossRef

Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma

Oleg V. Grinchuk, Surya P. Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce Kah‐Hoe Chow, Vladamir A. Kuznetsov

Molecular therapies and precision medicine for hepatocellular carcinoma

Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn

Nature Reviews Clinical Oncology.2018; 15(10): 599. CrossRef

Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib

Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong

Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis

Tumor Biology.2017; 39(6): 101042831770742. CrossRef

Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma

Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon

Digestive Diseases and Sciences.2016; 61(9): 2568. CrossRef

125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma

Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang, Meng Xu

World Journal of Gastroenterology.2016; 22(21): 5033. CrossRef

Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor

Wenya Zhou, Xiaoling Du, Fengju Song, Hong Zheng, Kexin Chen, Wei Zhang, Jilong Yang

MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

Ming-Hua Hu, Chen-Yang Ma, Xiao-Ming Wang, Chen-Dong Ye, Guang-Xian Zhang, Lin Chen, Jin-Guo Wang

NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report

E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N.